Eisai (ESAIY) and Biogen (BIIB) announced that humanized anti-soluble aggregated amyloid-beta monoclonal antibody Leqembi has been approved in Israel as a treatment of Alzheimer’s disease. Treatment with Leqembi should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials, the companies stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen announces Hong Kong has approved Leqembi to treat Alzheimer’s
- AI Could Revolutionize Drug Discovery: A Look at Key Players
- Eisai downgraded to Neutral from Buy at BofA
- Class Action Lawsuit against Biogen, Inc. (NASDAQ:BIIB)
- Biogen down 2% after Eli Lilly gets FDA approval for Alzheimer’s drug